I call this meeting to order.
Welcome, everyone, to meeting 24 of the House of Commons Standing Committee on Health. Today's meeting is taking place in a hybrid format, pursuant to the Standing Orders.
I would like to remind participants of the following points. For those participating by video conference, click on the microphone icon to activate your mic, and please mute yourself when you are not speaking. I remind you that all comments should be made through the chair.
Pursuant to Standing Order 108(2) and the motion adopted by the committee on Tuesday, September 23, 2025, the committee shall commence its study on Canada's pharmaceutical sovereignty.
I would like to welcome our witnesses today. We have, from Apotex, Jeff Watson, president and chief executive officer; as an individual, Michel Bouvier, professor; Julian M. Somers, full professor, by video conference; from the Canadian Generic Pharmaceutical Association, Jim Keon, president, and Jody Cox, vice-president; from the Canadian Pharmaceutical Manufacturers and Exporters Alliance, Terry Creighton, president; and from Innovative Medicines Canada, Bettina Hamelin, president and CEO, and Michael Dietrich, vice-president, market access and policy, by video conference.
Welcome, everyone. We have quite a list lined up for this afternoon.
Yes, sir, go ahead.
